Oragenics Inc (OGEN): Fred Telling , director of Oragenics Inc purchased 969,180 shares on Jun 30, 2016. The Insider buying transaction was reported by the company on Jul 1, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.52 per share for a total value of $499,999.97 , the company said in a SEC Form 4 Filing.
Shares of Oragenics Inc (OGEN) ended Wednesday, Jun 29, 2016 session in red amid volatile trading. The shares closed down -0.062 points or -10.47% at $0.53 with 34,932 shares getting traded. Post opening the session at $0.5916, the shares hit an intraday low of $0.5018 and an intraday high of $0.6205 and the price vacillated in this range throughout the day. The company has a market cap of $21 M and the number of outstanding shares has been calculated to be 4,00,58,540 shares. The 52-week high of Oragenics Inc is $3.87 and the 52-week low is $0.5.
Oragenics Inc. is a biopharmaceutical company. The Company develops markets and sells oral cavity probiotics products for humans and pets under the brand names Evora and ProBiora. The Company is developing its antibiotic product candidate MU1140 as well as other homolog antibiotic product candidates researching Live Biotherapeutic Products (LBPs) commercializing its ProBiora3 probiotic products and has other product candidates including SMaRT Replacement Therapy positioned for out licensing or partnering. MU1140 is an antibiotic that is active against all Gram positive bacteria. ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria including Streptococcus oralis KJ3 Streptococcus uberis KJ2 and Streptococcus rattus JH145 which promotes fresher breath whiter teeth and supports overall oral health. LPT3-04 is a natural occurring dietary substance that supports weight loss in overweight men and women.